Tumor Mutational Burden: Clinical and Diagnostic Utilization in Oncology
Lauren Ritterhouse MD, PhD
Susan Hsiao MD, PhD
This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.
This webinar will cover the background and rationale for the use of tumor mutational burden (TMB) as a biomarker for immunotherapy in oncology. The various biomarkers that have been evaluated for immunotherapy will be explored and a discussion of TMB’s role and use in oncology will be made. The course will cover an overview of immunotherapy drugs, targets, and tumor types for which TMB has been used as a biomarker.
- Define TMB and the rationale for its use as a biomarker for immunotherapy in oncology
- Describe the clinical utilization of TMB in oncology
Recording Date: June 27, 2018
Duration: 1 hr
Level of Instruction: Basic
CE Credit for this course has expired.
This webinar is part 1 of a three-part series exploring how measuring tumor mutational burden can improve patient care.
For more information on this series, please go here.
This program has been supported through an educational grant from Bristol-Myers Squibb.
Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.